229 related articles for article (PubMed ID: 29750396)
1. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Manley PE; Trippett T; Smith AA; Macy ME; Leary SES; Boklan J; Cohen KJ; Goldman S; Kilburn LB; Dhall G; Devin J; Herzog CE; Partap S; Fauchet F; Badreddine E; Bernard JP; Chi SN
Pediatr Blood Cancer; 2018 Sep; 65(9):e27217. PubMed ID: 29750396
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
Lockhart AC; Sundaram S; Sarantopoulos J; Mita MM; Wang-Gillam A; Moseley JL; Barber SL; Lane AR; Wack C; Kassalow L; Dedieu JF; Mita AC
Invest New Drugs; 2014 Dec; 32(6):1236-45. PubMed ID: 25117475
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
Fumoleau P; Trigo JM; Isambert N; Sémiond D; Gupta S; Campone M
BMC Cancer; 2013 Oct; 13():460. PubMed ID: 24099585
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.
Diéras V; Lortholary A; Laurence V; Delva R; Girre V; Livartowski A; Assadourian S; Semiond D; Pierga JY
Eur J Cancer; 2013 Jan; 49(1):25-34. PubMed ID: 22975213
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
Sarantopoulos J; Mita AC; He A; Wade JL; Hsueh CT; Morris JC; Lockhart AC; Quinn DI; Hwang J; Mier J; Zhang W; Wack C; Yin J; Clot PF; Rixe O
Cancer Chemother Pharmacol; 2017 Feb; 79(2):339-351. PubMed ID: 28058445
[TBL] [Abstract][Full Text] [Related]
6. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2016 Sep; 115(7):784-8. PubMed ID: 27607471
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
9. A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA).
Kang YK; Ryoo BY; Yoon S; Shen L; Lee J; Wei C; Zhou Y; Ryu MH
Cancer Chemother Pharmacol; 2015 Feb; 75(2):309-18. PubMed ID: 25486878
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
[TBL] [Abstract][Full Text] [Related]
11. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Rixe O; Puzanov I; LoRusso PM; Cohen RB; Morris JC; Olowokure OO; Yin JY; Doroumian S; Shen L; Olszanski AJ
Anticancer Drugs; 2015 Aug; 26(7):785-92. PubMed ID: 26020806
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.
Horton TM; Ames MM; Reid JM; Krailo MD; Pendergrass T; Mosher R; Reaman GH; Seibel NL;
Pediatr Blood Cancer; 2008 Apr; 50(4):788-92. PubMed ID: 17668866
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
